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ABSTRACT
Cholera, caused by the secretion of cholera toxin (CT) by Vibrio cholerae within
the intestinal lumen, triggers massive secretory diarrhea which may lead to lifethreatening dehydration. CT is an AB5-type protein toxin that is comprised of an
enzymatically active A1 chain, an A2 linker, and a cell-binding B pentamer. Once
secreted, the CT holotoxin moves from the cell surface to the endoplasmic reticulum
(ER) of a host target cell. To cause intoxication, CTA1 must be displaced from
CTA2/CTB5 in the ER and is then transferred to the cytosol where it induces a diarrheal
response by stimulating the efflux of chloride ions into the intestinal lumen.
Protein disulfide isomerase (PDI), a resident ER oxidoreductase and chaperone,
is involved in detaching CTA1 from the holotoxin. The PDI domain(s) that binds to
CTA1 and precisely how this interaction is involved in CTA1 dissociation from the
holotoxin are unknown. The goal of this project is to identify which domain(s) of PDI is
responsible for binding to and dislodging CTA1 from the CT holotoxin. Through
incorporation of ELISA, surface plasmon resonance (SPR), and Fourier transform
infrared (FTIR) spectroscopy techniques in conjunction with a panel of purified PDI
deletion constructs, this project aims to provide important molecular insight into a
crucial interaction of the CT intoxication process.
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BACKGROUND
Impact of Cholera
Cholera is a disease that causes severe symptoms similar to food poisoning, such
as nausea, fever, and vomiting, as well as massive secretory diarrhea. The copious loss
of water, up to a quart per hour, from the extreme diarrheal symptom can lead to lifethreatening electrolyte imbalance and dehydration if left untreated (Mayo Clinic, 2014).
As a result of electrolyte imbalance, there can be a severe drop in blood pressure and
blood oxygen levels leading to hypovolemic shock. Hypovolemic shock can cause
death in minutes.
Since 1817, there have been seven cholera pandemics. The disease is currently
endemic in over 50 countries (Harris, et al., 2012). The World Health Organization
estimates there are approximately 3-5 million global cases of cholera leading to 100,000120,000 deaths annually (WHO, Cholera Facts Sheet, 2014). Cholera continues to be a
serious health problem in Africa, Asia and Latin America (WHO, Cholera Facts Sheet,
2014). In addition to health care concerns, cholera epidemics can also have massive
economic consequences. Panic over outbreaks can lead to tourism and travel advisories
being put into place, as well as agricultural import restrictions (WHO, Global Epidemics
and Impact of Cholera, 2015). These ramifications can cause a devastating blow to the
economic structure of affected countries.
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The cholera transmission process is human-to-human through the fecal-oral
route, usually occurring when the feces of an infected patient comes in to contact with
groundwater. Ingestion of this contaminated groundwater then spreads the disease to
other individuals. This frequently happens in areas with stressed sewage systems, such
as areas exposed to natural disasters, communities subject to major flooding, and cities
in underdeveloped countries with high population densities (Harris, et al., 2012). The
cholera bacterium, Vibrio cholerae, can also persist in the environment in fresh or
saltwater, often growing on zooplankton or shellfish. In 1991, shellfish brought from
Latin America to the United States was determined to be the cause of five independent
cholera cases (WHO, 2002). It has been shown that the environmental distribution of
Vibrio cholerae is heightened in tropical aquatic environments (WHO, 2002).
Cholera can be diagnosed using darkfield microscopy to examine human stool
for vibrio-shaped (curved or comma-shaped rod) cells with a darting movement (Harris,
et al., 2012). The necessary incubation period for Vibrio cholerae is very short, from two
hours to five days (WHO, Cholera Facts Sheet, 2014). This brief incubation time of the
bacterium enhances the virulence of the disease. A definitive diagnosis for cholera can
be achieved through culture-based methods of a stool specimen using thiosulfatecitrate-bile salt sucrose agar plates (CDC, Diagnosis and Detection, 2015). Oral and
intravenous rehydration solutions, antibiotics, and vaccinations have been developed,
but present cholera control strategies have not proven effective globally (Harris, et al.,
2

2012). The preferred treatment for cholera is oral fluid replacement therapy (CDC,
Cholera- Vibrio Cholerae Infection, 2014). Yet, administration and obtainment of the
necessary clean, electrolyte-rich rehydration solutions is extremely difficult in
developing countries, especially during periods of natural disaster.
Cholera Toxin
Cholera intoxication begins after ingestion of the Gram-negative bacterium,
Vibrio cholerae, in a dose range of 106 to 1011 (Krauss, et al., 2003). Two strains of Vibrio
cholerae, O1 and O139, produce cholera toxin (CT) (Finkelstein, 1996). CT is the
virulence factor responsible for the life-threatening secretory diarrhea associated with
the cholera disease. CT is produced by the bacterium within the infected intestine and
is secreted into the intestinal lumen where it begins its trek into the host epithelial cell
by binding to ganglioside GM1 recognition sites on the intestinal plasma membrane
(Wernick, Chinnapen, Cho, & Lencer, 2010). The toxin then enters the cell by an
endocytosis process and proceeds to travel via a Golgi retrograde transport mechanism
from the plasma membrane and the trans-Golgi Network to its ultimately desired
destination, the endoplasmic reticulum (ER) (Wernick, Chinnapen, Cho, & Lencer,
2010). CT is an AB5-subunit toxin with a toxic A domain and a cell-binding pentamer B
domain (Figure 1). This pentameric structure of CTB allows the toxin to bind up to five
GM1 molecules at once (Wernick, Chinnapen, Cho, & Lencer, 2010). The A subunit of
CT is comprised of an A2-chain (CTA2) and an enzymatically active A1-chain (CTA1).
3

CTA1 relies on a disulfide bond and non-covalent linkages to bridge CTA2, which noncovalently attaches to the central pore of the holotoxin B-subunit (Wernick, Chinnapen,
Cho, & Lencer, 2010). CTA2 contains a KDEL amino acid sequence that acts as a target
for the migration of CT to the ER (Odumosu, Nicholas, Yano, & Langridge, 2010).

Figure 1: Cholera Toxin Structure. Catalytic CTA1 subunit; Linker CTA2 subunit; Cell-binding CTB5
pentamer. (Wernick, Chinnapen, Cho, & Lencer, 2010)

The target of CT is in the cytosol of the host intestinal epithelial cells. In order for
CT to cause intoxication, CTA1 needs to be displaced from the holotoxin and
transferred from the ER into the cytosol where it causes the diarrheic response
(Wernick, Chinnapen, Cho, & Lencer, 2010). Both the disulfide bond and the noncovalent linkages between the A1 and A2 subunits must be disrupted in order for this
displacement to occur (Taylor, et al., 2014). Once CT is exposed to the resident redox
state of the ER, the disulfide bond between CTA1 and CTA2 is reduced (Majoul, Ferrari,
4

& Soling, 1997). However, reduction of the disulfide bond between CTA1 and CTA2
within the redox environment of the ER is not sufficient to cause dissociation of the A1
subunit (Mekalanos, Collier, & Romig, 1979). Even after the disulfide bond is reduced
in the ER, CTA1 and CTA2 remain folded together due to the remaining extensive noncovalent bonding network between them. Reduced CTA1 must be physically displaced
from the holotoxin by an interaction with a resident ER protein, PDI (Taylor, et al.,
2014).
As a thermally unstable protein, when CTA1 is removed from the CTA2/CTB5
complex, it spontaneously assumes a disordered conformation at 37°C (physiological
temperature) (Pande, et al., 2007). This unfolded conformation allows the A1-subunit to
be recognized as an ER-associated degradation (ERAD) substrate for retro-translocation
into the cytosol (Pande, et al., 2007). The ERAD process acts as a quality control system
to remove misfolded proteins from the ER to the cytosol for degradation by the
ubiquitin-protease system (Lecker, Goldberg, & Mitch, 2006). Ubiquitin posttranslational modification acts a signal for proteosomal degradation of the conjugated
protein (Lecker, Goldberg, & Mitch, 2006). This occurs by recognition and binding of
exposed lysine residues on the unfolded protein of interest by ubiquitin. CTA1 lacks
substantial lysine residues, allowing it to escape degradation by ubiquitin processes in
the cytosol (Rodighiero, Tsai, Rapoport, & Lencer, 2002) (Pande, et al., 2007) (Hazes &
Read, 1997). An interaction with Hsp90 and lipid rafts allows CTA1 to regain a folded
5

conformation in the cytosol (Burress, Taylor, Banerjee, Tatulian, & Teter, 2014) (Ray,
Taylor, Banerjee, Tatulian, & Teter, 2012).
Once refolded, the cytosolic A1-chain modifies Gsα through ADP-ribosylation to
lock the protein in the GTP-bound conformation in order to trigger the continual
activation of adenylate cyclase and the rapid production of cAMP (Wernick,
Chinnapen, Cho, & Lencer, 2010). The increased production of cAMP leads to cAMP
binding of the inhibitory subunits of protein kinase A (PKA) (Fox, 2010). Upon binding
of cAMP to PKA, the inhibitory PKA subunits are released from the catalytic PKA
subunits allowing activation of the kinase (Fox, 2010). Activation of PKA then causes
changes in phosphorylation states of intestinal cellular proteins, most important of
which is the cystic fibrosis transmembrane regulator. Phosphorylation of this chloride
channel results in the intestinal chloride secretion resulting in the hallmark massive
diarrhea of cholera (Fox, 2010). This process is illustrated in Figure 2 below.

6

Figure 2: Cholera Intoxication Process. Cholera toxin, secreted by Vibrio cholerae in the intestinal lumen,
binds to GM1 receptors on the plasma membrane of host intestinal epithelial cells. The toxin is internalized
and brought to the ER through the Golgi. CTA1 dissociates in the ER and is exported from into the cytosol
where the toxin target is located and toxic effects occur. (Clemens, Shin, Sur, Nair, & Holmgren, 2011)

Protein Disulfide Isomerase
The ER-localized host protein, PDI, is responsible for removing reduced CTA1
from the holotoxin. PDI is of the thioredoxin superfamily and a resident ER protein
with intrinsic oxidoreductase and chaperone activity. The protein has an abb’xa’c
structural orientation comprised of two catalytic domains (a & a’) separated by two
non-catalytic domains (b & b’), a short x-linker, and a C-terminal extension (c), as
shown in Figure 3 (Appenzeller-Herzog & Ellgaard, 2008). The a and a’ domains of PDI
possess oxidoreductase capability.
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Figure 3. PDI Structure and Domain Organization. PDI has an abb’xa’c structural orientation comprised
of two catalytic domains (a & a’) separated by two non-catalytic domains (b & b’), a short x-linker, and a
C-terminal extension (c). The a and a’ domains are thioredoxin domains. (Gruber, Cemazar, Begona,
Martin, & Craik, 2006)

The linked but independent oxidoreductase and chaperone activities of PDI
allow it to facilitate proper folding of newly formed secretory proteins, prevent the
aggregation of misfolded proteins, and assist in elimination of misfolded proteins
through the ERAD system within the ER (Taylor, et al., 2014).
Functional Interactions Between CT and PDI
Once CT arrives within the ER, an interaction between PDI and the toxin is
necessary for successful intoxication. PDI can assist in the reduction of the
CTA1/CTA2 disulfide bond (Majoul, Ferrari, & Soling, 1997), but its critical role
involves physical displacement of the CTA1 subunit from the rest of the holotoxin
(Taylor, et al., 2014). Only after dissociation from the CTA2/CTB5 complex, can the
CTA1 subunit be exported out of the ER to its final destination within the cytosol and
8

begin its catalytic activity (Wernick, Chinnapen, Cho, & Lencer, 2010). CT disassembly
is necessary because CTA1 instability and unfolding is only possible after its removal
from the CTA2/CTB complex (Pande, et al., 2007).
The method of removal of CTA1 from CTA2 and CTB5 begins with the reduction
of the CTA1/CTA2 disulfide bond. This reduction, however, is not sufficient for
holotoxin disassembly (Mekalanos, Collier, & Romig, 1979). In addition to the disulfide
reduction, a crucial interaction between CT and PDI is required which begins by PDIholotoxin binding. It has been shown that PDI in the reduced state interacts with the
folded, holotoxin-associated CTA1 subunit (Taylor, Banerjee, Ray, Tatulian, & Teter,
2011) (Tsai, Rodighiero, Lencer, & Rapoport, 2001). This interaction causes a
spontaneous loss of structure in PDI but not CTA1 (Taylor, Banerjee, Ray, Tatulian, &
Teter, 2011). This unfolding of PDI is thought to result in an expansion of the
hydrodynamic radius of the protein that acts as a type of wedge to physically displace
the reduced A1 subunit from the remaining holotoxin (Taylor, et al., 2014), as shown in
Figure 4.
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Figure 4: The Wedge Model of PDI-mediated Toxin Disassembly. The binding of PDI to CTA1 triggers
a spontaneous unfolding of PDI resulting in the expansion of PDI’s hydrodynamic radius. This expansion
acts in a wedge-like fashion to displace the CTA1 subunit from the CTA2/CTB 5 complex. The release of
CTA1 from the holotoxin results in the spontaneous loss of structure. PDI is than able refold back into its
original ordered state (Taylor, et al., 2014). Schematic generously provided by Patrick Cherubin.

PDI with a 400 mM EDC treatment to hold the protein in a folded conformation
resulted in binding but no displacement of the A1 subunit (Taylor, et al., 2014).
The unfolding of PDI after contact with CTA1 is related to its chaperone
function, reversible, and necessary for holotoxin disassembly as well as cholera
intoxication (Taylor, et al., 2014). PDI deficient cell lines, as well as sole loss of PDI’s
chaperone function but not oxidoreductase function, result in CT resistance (Taylor, et
al., 2014) (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011). Upon separation from
CTA2/CTB5, CTA1 spontaneously undergoes a loss of structure and is recognized as an
ERAD substrate (Massey, et al., 2009).
Once unfolding of CTA1 occurs, PDI is released from the A1-substrate (Taylor,
Banerjee, Ray, Tatulian, & Teter, 2011). It was previously believed that an interaction of
PDI with an ER oxidase, resulting in a change in oxidation state, allowed for the release
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of its CTA1 substrate binding partner (Tsai & Rapoport, Unfolded cholera toxin is
transferred to the ER membrane and released from protein disulfide isomerase upon
oxidation by Ero1, 2002). However, more recent studies have shown that PDI does not
bind or stay bound to unfolded CTA1, thus indicating that PDI is released at the time of
CTA1 unfolding (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011). As shown through
techniques utilizing PDI deficient cell lines, PDI does not play a role in the translocation
of free CTA1 from the ER to the cytosol (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011).
Thus, it seems that PDI’s primary role in CT intoxication is in the displacement of
CTA1. In addition, studies have shown that PDI only interacts with CTA1 and not
CTA2 or CTB5 (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011). When PDI is in the
presence of only CTA2/CTB, there is no binding observed.
Overall, after binding to CTA1, PDI expands its hydrodynamic radius in a way
that physically pushes the A1 subunit off of the CTA2/CTB5 complex in a wedge-like
fashion (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011). CTA1 is then able to
spontaneously unfold and is recognized as an ERAD substrate for transport into the
cytosol (Massey, et al., 2009). Once in the cytosol, CTA1 is then refolded and able to
commence its catalytic activity (Wernick, Chinnapen, Cho, & Lencer, 2010). This
interaction between PDI and CT within the ER is critical for successful intoxication.
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INTRODUCTION
The area of cholera I have researched is the PDI-mediated dissociation of CTA1
from the CT holotoxin. Cholera intoxication happens when CTA1 reaches the cytosol,
which is only possible if CTA1 is dissociated from the holotoxin and assumes an
unfolded conformation in the ER (Wernick, Chinnapen, Cho, & Lencer, 2010). CTA1
must be physically displaced from the cholera holotoxin (Taylor, et al., 2014). Structural
and biochemical studies have shown that PDI, an ER oxidoreductase protein, is actively
involved in the CTA1 holotoxin dissociation (Taylor, et al., 2014) (Tsai, Rodighiero,
Lencer, & Rapoport, 2001). Furthermore, PDI-deficient cells are completely resistant to
CT (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011).
Originally, PDI in the reduced form was thought to actively unfold CTA1 upon
binding, causing displacement of the subunit from the rest of the toxin (Tsai,
Rodighiero, Lencer, & Rapoport, 2001). It is true that PDI must be in the reduced form
in order to recognize the A1-subunit (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011), but
recent biophysical analysis reveals that PDI does not actively unfold CTA1 (Taylor,
Banerjee, Ray, Tatulian, & Teter, 2011). Rather, recent studies in the Teter lab have
found that PDI itself unfolds when bound to the holotoxin associated CTA1 subunit,
thus dislodging the subunit from the holotoxin (Taylor, Banerjee, Ray, Tatulian, & Teter,
2011). In addition, PDI’s interaction with CTA1 is able to remove the subunit while
CTA1 is held in a folded state, indicating that the displacement of CTA1 from the
12

holotoxin does not involve its active unfolding by PDI (Taylor, Banerjee, Ray, Tatulian,
& Teter, 2011). Considering this new observation, it is possible that PDI unfolding upon
contact with CTA1 acts as a type of lever to dislodge CTA1 from the holotoxin with the
expansion of its hydrodynamic radius, providing a molecular explanation for CT
disassembly. In turn, the dissociated A1 subunit unfolds and is recognized as an ERAD
substrate for delivery into the cytosol of the host cell.
The exact domain(s) of PDI that binds to CTA1 and precisely how this protein
interaction is involved in CTA1 holotoxin dissociation is unknown. The research in this
project attempts to address the following outstanding questions: Which domain(s) of
PDI assists in the reduction of the CTA1/CTA2 disulfide bond? Which domain(s) binds
to CTA1? Which domain(s) of PDI is responsible for dislodging CTA1 from the CT
holotoxin, and does this domain unfold? It is possible that the binding domain(s) alone
may not be solely responsible for the displacement of CTA1 from the holotoxin. Hence,
it is important to determine which domain(s) binds to CTA1, as well as which
domain(s) is necessary to displace CTA1.
This project utilizes SDS-PAGE gel electrophoresis, surface plasmon resonance,
Fourier transform infrared (FTIR) spectroscopic analysis, and enzyme-linked
immunosorbent assay (ELISA) techniques to explore the PDI-mediated disassembly of
the cholera holotoxin. Through the results of these assays, we have made strides
toward the elucidation of answers to these unresolved questions.
13

MATERIALS AND METHODS
Materials
CT holotoxin and anti-CTB5 were purchased from Calbiochem (La Jolla, CA).
Anti-PDI was purchased from Enzo Life Sciences (Farmingdale, NY). GSH was
purchased from Fischer BioReagents (Fair Lawn, NJ). CTA, PDI, and ganglioside GM1
were purchased from Sigma-Aldrich (St. Louis, MO). Clear, untreated, non-sterile
ELISA plates were purchased from MidSci (St. Louis, MO). The anti-CTA1 monoclonal
antibody 35C2 (Holmes & Twiddy, 1983) used in this project was a gift from Dr.
Randall K. Holmes (University of Colorado School of Medicine). A pOLR130 plasmid
encoding N-terminal His6-tagged, full-length, human PDI was kindly provided by Dr.
Lloyd Ruddock (University of Oulu, Finland). The Escherichia coli BL21 DE3 strains
transformed with DNA plasmid encoding the panel of truncated, N-terminal His6tagged PDI deletion constructs used for construct purification in this project were
generously produced and provided by Dr. Lucia Cilenti.
PDI Construct Purification
Bacterial recombinant protein expression and Talon affinity chromatography
techniques were used to purify full-length PDI and a panel of truncated, His-tagged
PDI deletion constructs. Escherichia coli strain BL21 DE3 transformed with DNA
plasmid encoding a panel of truncated, N-terminal His6-tagged PDI deletion constructs
were inoculated into 10-20 ml of LB broth with kanamycin (40 μg/ml) or ampicillin (50
14

μg/ml). The cultures were grown overnight at 37˚C with shaking. The cultures were
then expanded in a 1:100 dilution into 1 liter of LB broth with kanamycin or ampicillin.
The cultures are allowed to grow at 37˚C with shaking until the O.D.600 reached 0.8-1.0.
The cultures are subsequently induced with 2 mM IPTG for 4-6 hours. The cells were
pelleted at 6,000 rpm and 4˚C for 10 minutes. The supernatant was removed and the
cells were suspended in 5 ml of extraction buffer containing 1X PBS, 300 mM NaCl,
0.1% Triton X-100, 0.1 μl/ml DNAse, 100 μg/ml lysozyme, and 10 μl/ml His-PIC
(Sigma Aldrich). The cells were lysed with three 15 minute freeze/thaw cycles at -80˚C
and 37˚C. PDI is a soluble protein, so the supernatant is collected and syringe filtered to
eliminate any residual cellular debris.
Preparation of TALON beads were prepared as directed by the manufacturer
(Clontech, Mountain View, CA). After the TALON beads were equilibrated with
extraction buffer, the collected lysate was added to the bead resin and rotated overnight
at 4˚C. The resin was centrifuged at 1,500 rpm for 5 minutes and the supernatant was
removed. The pellet was resuspended in 10 ml of wash buffer containing extraction
buffer with a final concentration of 600 mM NaCl and 0.1% Triton X-100. The resin was
agitated at room temperature for 15 minutes and then centrifuged at 700 g for 5
minutes. The wash step was repeated 2 more times with wash buffer. 1 mL of
extraction buffer was then added to the washed resin, and the pellet was resuspended.
The resin was transferred to a 2 ml gravity flow column and allowed to settle. The
15

wash buffer was allowed to flow through the resin. 2 ml of extraction buffer containing
increasing concentration of imidazole (10, 15, 20, 25, 35, 40 and 50 mM) was used to
elute the purified His6-PDI from the TALON resin. 0.5 ml fractions were collected
during each elution and stored at -20˚C until needed. SDS-PAGE using 15%
polyacrylamide gels and Coomassie Brilliant Blue stain were used to visualize 2 μg
samples the His6-PDI and verify the purity of the samples.
Reduction Assay
To determine the reduction capability of the disulfide bond between CTA1 and
CTA2 by the a and a’ oxidoreductase domains of PDI, 10 μg of the purified full-length
PDI, the abb’x PDI construct, and the bb’xa’c PDI constructs were pre-reduced with 1
mM GSH and PBS in a 20 μl reaction for 30 minutes at room temperature (25˚C). 4 μl of
each sample was then incubated with 2 μg of disulfide-linked CTA1/CTA2 and PBS in
a 20 μl reaction for 1 hour in a 37˚C water bath, yielding a final concentration of 2 μg
PDI and 250 nm GSH per sample. 250 nm GSH without PDI added to 2 μg
CTA1/CTA2 was included in this step as a negative control. Non-reducing sample
buffer, lacking β-mercaptoethanol, was then added to the samples, boiled for 5 minutes,
and run on a 15% polyacrylamide gel. Coomassie staining was used to visualize the
results.

16

Surface Plasmon Resonance (SPR)
SPR was used to monitor the real-time PDI-mediated disassembly of the cholera
holotoxin. The SPR technique utilizes a gold-plated sensor slide that is coated in a
protein sample, a flow channel where an additional protein sample in liquid is
continuously flowed over the sensor slide, a polarized light source directed toward the
sensor slide, and a detector to analyze the changes in the refractive index of the light
beam indicating protein-protein interactions. A change in refractive index unit (RIU) is
a reflection of change in binding and interaction between the two proteins of interest.
Binding is seen as a rise in RIU, indicating an increase of mass bound to the sensor
plate. A drop in RIU indicates a loss of mass on the sensor slide, and a drop in RIU
below the initial baseline reading can be interpreted as loss of mass of the initial protein
coated on the sensor plate. This technique was used with cholera holotoxin-coated
sensor slides, and protein disulfide isomerase as the binding protein in the flow
channel.
Interactions between the CT holotoxin and the purified PDI constructs were
examined with a Reichert (Depew, NY) SR7000 SPR Refractometer. A gold plated SPR
sensor slide was coated with ganglioside GM1 and CT holotoxin as previously
described in (Massey, et al., 2009). PBST was then perfused over the sensor slide for 10
minutes at 37˚C to generate a baseline measurement corresponding to the mass of the
bound CT holotoxin on the plate. Each PDI construct was then individually perfused
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over subsequent holotoxin coated sensor plates with a final concentration of 0.1 μg/μl
in a PBST solution containing 1 mM GSH. PDI samples and 1 mM GSH were allowed
to incubate for 10 minutes at room temperature before each experiment. After removal
of PDI from the perfusion buffer, antibodies were perfused over the plate in PBST
consecutively at the following dilutions to detect the presence or absence of PDI, CTA1,
and the CTA2/CTB5 complex: anti-PDI antibody, 1:200; anti-CTA1 monoclonal
antibody, 1:200; and anti-CTB antibody, 1:500. All steps were performed at 37˚C with a
perfusion flow rate of 41 μl/minute. Control experiments were performed to show that
holotoxin disassembly did not occur in the presence of 1 mM GSH without PDI or with
PDI in the absence of GSH. All RIU values are relative in these experiments.
Fourier Transform Infrared Spectroscopic (FTIR) Analysis
FTIR is a technique used to analyze protein secondary structure by measuring
the wavelength and intensity of infrared (IR) radiation absorption of proteins (Kong &
Yu, 2007). FTIR spectroscopy was used to monitor the structural confirmation of PDI in
the presence of CTA1. FTIR allows for the determination of two protein structures
when in the presence of each other by 13C-labeling of one of the proteins. This 13C label
does not affect protein structure but does allow for the distinction of the individual
protein structures by a spectral downshift of only the labeled protein. This downshift
allows for both of the protein structures to be resolved in the same spectra. Of the
produced spectra, the amide I region (1700-1600 cm-1) absorptions, where peptide bond
18

carbonyl stretch vibrations are detected, is the most indicative of protein secondary
structure (Kong & Yu, 2007).
Protein samples for FTIR measurements were prepared in a D2O-based buffer
containing 10 mm sodium borate pH 7.0. The samples contained either unlabeled PDI,
or both unlabeled PDI and uniformly 13C-labeled CTA1 at a 1:1 molar ratio. Each
sample contained 1 mM GSH. FTIR experiments were performed using a Jasco 4200
FTIR spectrometer at 0.964 cm−1 spectral resolution and a set resolution of 1 cm−1. The
absorbance spectra were calculated using the respective buffers as reference and were
corrected by subtraction of water vapor contribution, smoothing, and baseline
correction in the amide I region. Curve fitting was conducted using the component
frequencies from the second derivative spectra, as described in (Tatulian, Attenuated
total reflection Fourier transform infrared spectroscopy: a method of choice for studying
membrane proteins and lipids, 2003). No appreciable signals from the second
derivative spectra were detected in the region above 1700 cm−1.
Enzyme-Linked Immunosorbent Assay (ELISA)
96-well ELISA plates were coated in ganglioside GM1 as described by an ELISA
plate GM1 coating procedure (Bech, Jakobsen, & Orntoft, 1994). The coated plates can
be stored at 4˚C in 0.05% PBST. The plates are then washed three times with PBST,
blocked with 1% BSA in PBS for one hour at room temperature, and washed again three
times. CT is added to each well at a concentration of 5 ng/μl in PBST for one hour at
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37˚C, and then washed three times. PDI is added to each well at a concentration of 2.5
ng/μl with 1 mM GSH in PBST for one hour at room temperature or 37˚C. The plate is
then washed three times. CTA1 monoclonal primary antibody is added at a 1:50
dilution in a 0.1% BSA-PBS solution for one hour at 37˚C. The plate is washed, and
HRP-conjugated mouse IgG secondary antibody is added at a 1:1,000 dilution in a 0.1%
BSA-PBS solution for one hour at 37˚C. After an additional wash cycle, TMB at room
temperature is added to the plate and the reaction is allowed to incubate for 10 minutes
at room temperature. A 2N H2SO4-PBS stop solution is then added, and the optical
density results are read at 450 nm with a Tecan Microplate Reader.
This process is summarized in Figure 5. The three possible results we expected
from this ELISA were: a) the PDI deletion construct would bind and displace CTA1; b)
the PDI deletion construct would be able to bind, but not displace CTA1; c) the deletion
construct would not be capable of binding or displacing CTA1 (Figure 5).
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Figure 5: ELISA Method and Possible Results Schematic.

Each condition was performed with 8 replicate samples, and controls were run to show
that there is no holotoxin dissociation with 1 mM GSH alone or PDI in the absence of
GSH.
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RESULTS
Full-length PDI and PDI Construct Purification
Full-length PDI and PDI constructs were purified using the TALON affinity
chromatography purification procedure as explained in the methods section. A
schematic for the domains of PDI and the deletion constructs can be seen in Figure 5,
corresponding to the purification results in Figure 6. SDS-PAGE electrophoresis and
Coomassie Brilliant Blue stain were used to verify the purity of the PDI constructs
(Figure 6). These constructs were used for the experiments of this project.

Figure 6: Schematic of PDI and PDI Deletion Construct Domains.
capability are indicated with a “CGHC”.
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Domains with oxidoreductase

Figure 7: Purification of Full-length PDI and PDI Deletion Constructs. Lane 1: Molecular weight
markers; Lane 2: Commercially bought PDI; Lane 3: Full-length purified PDI; Lane 4: PDI domain abb’x;
Lane 5: PDI domain bb’xa’c; Lane 6: PDI domain bb’x.

PDI a and a’ Domains are Able to Assist in the Reduction of the CTA1/CTA2
Disulfide Bond
Before displacement of CTA1 from the CT holotoxin in the ER, the disulfide bond
linking CTA1 and CTA2 must be reduced. PDI has two domains that harbor
oxidoreductase capability, the a and a’ domains. A reduction assay, as described in the
methods section, was used to determine if either or both of these domains are able to
assist in reduction of the CTA1/CTA2 disulfide bond. Results from this experiment
utilizing PDI deletion constructs lacking either the a or a’ domains are shown in Figure
7. These results indicate that both pre-reduced a and a’ domains are able to take part in
this reduction process. A shift in CTA from a higher molecular weight to a lower
molecular weight indicates reduction of the disulfide bond. After reduction, addition of
non-reducing sample buffer, and boiling, CTA1 (molecular weight: ~25 kDa) can be
seen as the band shifts from the 30 kDa CTA1/CTA2 heterodimer to the 25 kDa CTA1
subunit. CTA2 (molecular weight: ~5 kDa) is not visible on the gel. Controls of CTA
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alone (lane 2), CTA with GSH only (lane 3), and CTA with pre-reduced full-length PDI
(lane 4) are used as negative and positive controls.

Figure 8: Reduction of CTA by PDI. Non-reducing SDS-PAGE and Coomassie staining was used to
visualize the reduction of 2) CTA by: 3) 250 ng GSH, 4) Full-length PDI, 5) abb’x PDI construct, and 6)
bb’xa’c PDI construct. All constructs were pre-reduced with 250 ng GSH.

The PDI a Domain is Required for CTA1 Disassembly, and the bb’x-Domains are
Sufficient for CT Binding.
In order for holotoxin disassembly to occur in the ER, CTA1 must be bound and
displaced by PDI. To test which domains are required for binding and disassembly of
the CT holotoxin, SPR utilizing the PDI deletion constructs was used to observe the
real-time PDI-mediated disassembly of CT. The PDI deletion constructs with 1 mM
GSH were perfused over a SPR sensor slide coated with CT. Binding of PDI to the
holotoxin is seen as a rise in RIU, indicating an increase in mass bound to the sensor
slide. A subsequent drop in RIU below that of the initial baseline measurement
(corresponding to mass of the initial bound holotoxin), can be interpreted as a loss of
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both PDI and CTA1 from the sensor slide. An increase in RIU after addition of PDI, but
no drop in RIU can be interpreted as binding of PDI without displacement. The
presence or absence of PDI, CTA1, and the CTA2/CTB5 complex can be determined
with an increase in RIU after the addition of corresponding antibodies.
A positive control experiment was run with full-length PDI with 1 mM GSH
perfused over the CT coated slide. A dramatic rise in RIU and then subsequent drop in
signal below the baseline value was seen after the addition of full-length PDI (Figure
8A). Addition of anti-PDI, anti-CTA1 monoclonal, and anti-CTB5 antibodies confirmed
holotoxin disassembly by the absence of PDI and CTA1, and the presence of CTB5.
When the abb’x deletion construct in the presence of 1 mM GSH was perfused over the
CT-coated sensor slide, a change in RIU signal was detected similar to that of the fulllength positive control (Figure 8B). A rapid rise in RIU was followed by a drop in RIU
below the baseline after PDI perfusion. This was again followed by an absence of
change in signal with the addition of anti-PDI and anti-CTA1 antibodies, but a rise in
RIU after the addition of anti-CTB5 antibodies. These results indicate that the abb’xdomain combination can bind and displace the CTA1 subunit. A repeat of this assay
using the bb’xa’c deletion construct shows binding, but no CTA1 disassembly (Figure
8C). The presence of PDI, CTA1, and CTB5 are all indicated by a rise in RIU after
addition of anti-PDI, anti-CTA1, and anti-CTB5 antibodies. Perfusion of the bb’x
deletion construct in the presence of 1 mM GSH produced results similar to that of the
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bb’xa’c construct (Figure 8D). Binding was observed but no displacement. Again, PDI,
CTA1, and CTB were all confirmed to be present on the plate by a rise in RIU after
subsequent addition of anti-PDI, CTA1, and CTB5 antibodies.

Figure 9: Holotoxin Binding and Disassembly. Real-time holotoxin binding and disassembly by PDI was
observed by SPR. Each perfusion buffer contained 1mM GSH. A) Full length, B) abb’x, C) bb’xa’c, and D)
bb’x PDI constructs were flowed over a CT coated sensor. Anti-PDI, anti-CTA1 monoclonal, and anti-CTB5
antibodies are added to the perfusion buffer at time points corresponding to the arrowheads. B and C
show that the a domain is required for holotoxin disassembly, and D shows that the bb’x domains are
sufficient for binding.

A comparison of the abb’x, bb’xa’c, and bb’x deletion construct results can be
interpreted as the requirement of the a domain for disassembly and the sufficiency of
the bb’x domains for binding of the CT holotoxin. Negative control experiments were
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performed to show that holotoxin disassembly did not occur in the presence of 1 mM
GSH alone or with PDI in the absence of GSH.
CTA1-PDI Interaction Results in PDI Loss of Structure
To explore the observation that PDI unfolding corresponds to holotoxin
disassembly, FTIR spectroscopy was used to monitor the structural confirmation of PDI
in the presence of CTA1. FTIR allows for the determination of two protein structures
when in the presence of each other by 13C-labeling of one of the proteins. This 13C label
does not affect protein structure but does allow for the distinction of the individual
protein structures by a spectral downshift of only the labeled protein. This downshift
allows for both of the protein structures to be resolved in the same spectra.
All FTIR experiments were run at 10˚C, in order to perform the experiments with
CTA1 in the folded conformation, and in the presence of 1 mM GSH, unless otherwise
stated. Results show that in the absence of CTA1, PDI in the folded confirmation
harbored a 33% α-helical, 45% β-sheet, and 19% irregular structure (Figure 9A). These
percentages were consistent with the secondary structural content predicted from the
crystal structure of PDI (Tian, Xiang, Novia, Lennarz, & Schindelin, 2006) and from
previously published FTIR traces for PDI alone with GSH, as well as for PDI with GSH
in the presence or absence of CTA1 (Taylor, et al., 2014). Once added to CTA1, the
percentage of α-helical and β-sheet content of PDI was reduced considerably to 18% αhelix and 31% β-sheet. This loss of defined structure was replaced by a rise in irregular
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structure to 45% (Figure 9B). This shift of PDI from an ordered to a disordered
conformation demonstrates an unfolding of PDI after interaction with CTA1. There
was no significant difference between the structure of PDI in the presence and absence
of GSH alone, and a loss of structure was not observed with PDI in the presence of
CTA1 without GSH (data not shown).

B

A

Figure 10: Effect of PDI-CTA1 Interaction on PDI Structure. FTIR was used to visualize the changes in
structure of PDI when in the absence (A), and presence of CTA1 (B). All experiments performed at 10˚C
and under reducing conditions with 1 mM GSH.

An ELISA Assay was Generated to Monitor Holotoxin Disassembly
An ELISA assay, as described in the methods section, was produced to monitor
PDI-mediated CT holotoxin disassembly. A clear, untreated, non-sterile 96-well plate
was coated in GM1 and holotoxin. These CT coated plates are able to be stored in PBST
at 4˚C. Results are gathered after a colorimetric reaction between the HRP, conjugated
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to a secondary antibody, and TMB followed by the addition of a 2N H2SO4-PBS stop
solution. The presence or absence of proteins of interest are indicated by the intensity
of the color from the reaction. The color intensity is proportional to the concentration of
the protein of interest present on the plate, as determined by analysis of a microplate
reader. Results produced from the addition of purified full-length PDI over a time
course of 1-60 minutes is shown in Figure 10A. This assay was run at 37˚C with 1 mM
GSH. Holotoxin disassembly appears to be time-dependent in this assay, with an
increasing loss of CTA1 from the plate with additional incubation time. Results from
the addition of PDI in the presence of 30 mM GSH for 1 hour at 25˚C (Figure 10B) and at
37˚C (Figure 10C) are also shown below. These results show a higher yield of CTA1
dissociation at 37˚C for this assay.
Presence or absence of CTA1 on the plate was determined by analysis of the
intensity of secondary CTA1 HRP-conjugated antibody colorimetric reactions with
TMB. Positive controls of CT with GSH only, and negative controls of wells with no
holotoxin were run in all three assays. This protocol is being optimized further for use
with the purified PDI deletion constructs.

29

Figure 11: PDI-Mediated Holotoxin Disassembly via ELISA. An ELISA assay was produced to monitor
the PDI-mediated CT holotoxin disassembly. GM1 and CT-coated plates were used for an ELISA using a
25 ng/μl commercially bought PDI with an incubation time course of 0, 1, 5, 15, 30, and 60 minutes at 37ºC
(A), and an ELISA using 2.5 ng/μl full-length PDI from a commercial vendor (CT + PDI) and purified, Histagged PDI (CT + PDI-His) with a 1 hour incubation time at 25º (B) or 37º (C), each reduced with 30mM
GSH. CT without the addition of PDI was used as a positive control, and wells with no toxin were used as
a negative control for each of these experiments. A 1:1,000 dilution of an anti-CTA1 monoclonal antibody
was used, and each condition involved 8 replicate samples.
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DISCUSSION
In order for a successful intoxication process to occur, CT must travel from the
cell surface to the ER. Within the ER, the disulfide bond linking CTA1 and CTA2 must
be reduced, and the reduced CTA1 subunit must be displaced from the CTA2/CTB5
complex by an interaction with PDI. This interaction is described as an expansion in the
hydrodynamic radius of PDI, allowing the protein to physically displace CTA1 in a
wedge-like fashion (Taylor, Banerjee, Ray, Tatulian, & Teter, 2011). In this work, the
domains of PDI that may assist in the reduction of the CTA1/CTA2 disulfide bond, as
well as the domains of PDI that are necessary to bind and displace CTA1 during this
critical interaction, have been explored.
Using a non-reducing SDS-PAGE, we were able to determine that both the a and
the a’ domains of PDI may assist in the reduction of the disulfide bond linking CTA1
and CTA2. These two domains harbor oxidoreductase capability and both were shown
to successfully reduce the CTA1/CTA2 complex after a 30 minute pre-reduction with 1
mM GSH (Figure 7). The minimal GSH concentration that was still present after the
PDI pre-reduction was controlled for with a sample of CTA and GSH only. This
minimal amount of GSH was not sufficient to reduce the disulfide bond. The ability of
either thioredoxin-like domain to reduce the CTA1/CTA2 disulfide bond suggests both
domains are in close proximity to the CTA1/CTA2 disulfide bond when PDI binds to
CT.
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SPR was used to monitor the real-time disassembly of the CT holotoxin by
purified full-length PDI and a panel of various PDI deletion constructs. The results
generated by these experiments indicate that the a domain is required for CTA1
displacement, and the bb’x domains are sufficient for holotoxin binding. Our results
lead us to the very interesting conclusion that the binding domains alone are not solely
responsible for holotoxin disassembly. Holotoxin disassembly was possible only when
the a domain of PDI was present in the deletion constructs. In addition, binding was
observed by all constructs, leading us to believe that a combination of the b, b’, and x
domains is responsible for toxin binding.
FTIR spectroscopy was used to show a shift from an ordered to a disordered
conformation of full-length PDI after binding to CTA1. It has been previously believed
that PDI actively unfolds CTA1, resulting in the dissociation of the subunit from the
holotoxin (Tsai, Rodighiero, Lencer, & Rapoport, 2001). In contrast, more recent studies
have shown that rather than CTA1 losing structure after PDI interaction, PDI itself
acquires an unfolded structural confirmation when bound to CTA1 (Taylor, Banerjee,
Ray, Tatulian, & Teter, 2011) (Taylor, et al., 2014). These results were confirmed by the
data generated from the FTIR experiment of this project. A significant loss of structure
in PDI was observed when in the presence of CTA1, as compared to when CTA1 is
absent.
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An ELISA protocol has been developed that incorporates a simple and
reproducible GM1 (Bech, Jakobsen, & Orntoft, 1994) and CT coating procedure. Results
from this present ELISA assays indicate that an increased incubation time of PDI and
CT results in a more efficient displacement of CTA1. Increased efficiency is also
achieved by performing the PDI-CT incubation at 37˚C, rather than at 25˚C.
Our work has established further insight into the crucial interaction between PDI
and CT within the ER during cholera intoxication. Overall, this work has shown that
the a domain is required for displacement of CTA1, the bb’x domains are sufficient for
holotoxin binding, and both the a and a’ domains may assist in the reduction of the
CTA1/CTA2 disulfide bond.
Future Directions
To further examine the results of this project, purification of deletion constructs
bb’, and b’x are being completed, and application of the SPR assay with these newly
purified deletion constructs will be used to further investigate the binding process.
Results generated from utilization of these constructs with SPR will indicate whether
binding of PDI to the holotoxin requires all three of the b, b’, and x domains, or a
combination of the three.
In addition, the FTIR assay utilized in this project will be used in conjunction
with the panel of PDI deletion constructs in order to determine if a loss of structure or
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unfolding of specific PDI domains corresponds to holotoxin disassembly. These results
would be used to confirm the SPR findings of this project.
Lastly, continued optimization of the ELISA assay is being explored for use with
the panel of purified PDI deletion constructs to further examine the CT binding and
disassembly capabilities of specific PDI domains. These results will also be used to
support our findings from the SPR and FTIR experiments as well.
In the future, we may be able to use our findings on this critical interaction to
design inhibitors that block PDI binding and CTA1 dissociation and the resulting toxic
effects in the cytosol.
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